Accellta Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Accellta General Information

Description

Developer of stem cell culture technologies designed to offer a range of revolutionary solutions for better affordability and quality of stem cell culture. The company's technologies offer custom-made solutions for mass production of high-quality human embryonic and induced pluripotent stem cells, progenitors, and differentiated cells for drug discovery, regenerative medicine, and research, enabling clinicians to provide a cost-effective genetic manipulation of the cells with enhanced uniformity and purity.

Contact Information

Website
www.accellta.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • 1 Rose Avenue
  • Malat Building, Technion City
  • Haifa 3200004
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accellta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Jun-2022 000 Completed Generating Revenue
3. Early Stage VC (Series A) 26-Oct-2014 000 000 00.000 Completed Generating Revenue
2. Grant 08-Jan-2014 $68.5K Completed Generating Revenue
1. Seed Round 01-Nov-2012 Completed Startup
To view Accellta’s complete valuation and funding history, request access »

Accellta Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Accellta’s complete cap table history, request access »

Accellta Patents

  • 19

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Accellta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021300644-A1 Mammalian livestock pluripotent stem cells from delayed embryos Pending 02-Jul-2020 0000000000
CA-3187845-A1 Mammalian livestock pluripotent stem cells from delayed embryos Pending 02-Jul-2020 0000000000
EP-4176046-A1 Mammalian livestock pluripotent stem cells from delayed embryos Pending 02-Jul-2020 0000000000
JP-2023532061-A Mammalian livestock pluripotent stem cells derived from delayed embryos Pending 02-Jul-2020 0000000000
US-20230220332-A1 Mammalian livestock pluripotent stem cells from delayed embryos Pending 02-Jul-2020 C12N5/0604
To view Accellta’s complete patent history, request access »

Accellta Executive Team (7)

Name Title Board Seat Contact Info
Michal Amit Ph.D Co-Founder, Chief Executive Officer & Chief Technology Officer
Yael Garfinkel Chief Financial Officer
Patrick Zhang Chairman
You’re viewing 3 of 7 executive team members. Get the full list »

Accellta Board Members (7)

Name Representing Role Since
Patrick Zhang Self Chairman 000 0000
Peretz Lavie Accellta Board Member 000 0000
Rona Samler Accellta Board Member 000 0000
You’re viewing 3 of 7 board members. Get the full list »

Accellta Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Accellta Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 SME Instrument Government 000 0000 000000 0
To view Accellta’s complete investors history, request access »

Ready to get started?

Request a free trial